Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON
Related Posts
Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or[...]
Balogh EP, Levit LA, Unger JM, Accordino MK, Chism DD, Kirkwood MK, Parsons HM, Patel MI, Peppercorn JM, Polite BN, Sedrak MS, Sharma P, Subbiah[...]
Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P,[...]